CN107362130B - 一种铜纳米粒凝胶载药系统及其制备方法和应用 - Google Patents
一种铜纳米粒凝胶载药系统及其制备方法和应用 Download PDFInfo
- Publication number
- CN107362130B CN107362130B CN201710591620.0A CN201710591620A CN107362130B CN 107362130 B CN107362130 B CN 107362130B CN 201710591620 A CN201710591620 A CN 201710591620A CN 107362130 B CN107362130 B CN 107362130B
- Authority
- CN
- China
- Prior art keywords
- copper
- nano
- drug
- gel
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/95—Involves in-situ formation or cross-linking of polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Abstract
本发明公开了一种铜纳米粒凝胶载药系统及其制备方法和应用,原料包括铜纳米,聚γ‑谷氨酸,壳聚糖、透明质酸、交联剂EDC/NHS,鼠李糖脂。本发明制得的纳米铜凝胶载药系统,可应用到医疗产品当中,尤其是在伤口敷料方面的应用。与现有的技术相比,本发明所获得的铜纳米粒凝胶载药系统,具有良好的生物相容性,抑菌性,首选铜纳米作为药物载体,鼠李糖脂作为药物分散剂,透明质酸作为凝胶稳固剂,形成的凝胶载药系统,保水性较高,失水率较低,药物包裹率较高,载药量较高,并且具有较高的可降解性,溶胀性能较好,原料廉价易得,生产工艺简单。
Description
技术领域
本发明属于医学技术领域,涉及一种铜纳米粒凝胶载药系统及其制备方法和应用。
背景技术
聚γ-谷氨酸是一种均聚氨基酸类高分子物质,通过谷氨酸的α-NH2和γ-COOH以酰胺键的形式结合在一起的,因此分子内存在的大量酰胺键以及分子间形成的氢键,其分子量很大,通常在200KD-20000KD左右。在自然界或者人体内,能降解成内源性物质谷氨酸,使得该分子具有良好的生物降解性,没有蓄积或者毒副作用;含有许多游离羧基,是一个聚负离子基的生物聚合物,具有极高的吸水保湿性能,易于和一些药物结合在一起生成相对稳定的复合物药物,是一类非常理想的可生物降解的医用高分子材料,作为药用载体,具有很高的价值。
目前,聚γ-谷氨酸类凝胶载药系统应用较多的为银离子、金离子,具有较高的抑菌效果,但是因其属于贵金属,成本很高,无形中增加了使用者的经济负担,从而限制了胶载药系统的发展应用。
发明内容
本发明针对现有技术中存在的上述不足,提供一种铜纳米粒凝胶载药系统及其制备方法,制备获得的载药系统,具有较高的生物相容性,抑菌性能良好。
本发明还提供了上述铜纳米粒凝胶载药系统的应用,由于具有较高的药物负载率,在烧伤,割伤等伤口处的创伤敷料,扭伤处的活血化瘀,舒筋活血,消除肿胀的膏药等医药产品,及其面膜、护手霜等美容护肤产品中具有广泛的应用。
本发明技术方案如下:
一种铜纳米粒凝胶载药系统,为致密的三维网状多孔结构,凝胶交联度35.4%以上,纳米铜包含率为98.84~99.86%,药物负载率为95.67~97.48%,吸水度为35.5~39.7g/g,药物包裹率为47.82~59.94%。
所述铜纳米粒凝胶载药系统,制备原料包括:纳米铜、壳寡糖、聚γ-谷氨酸、EDC/NHS交联剂、透明质酸、鼠李糖脂和负载药物。
进一步地,所述的纳米铜,粒度为50nm。
进一步地,所述的纳米铜与壳寡糖、聚γ-谷氨酸的质量比为0.1~0.3: 2~5:50~90。
进一步地,所述的 EDC/NHS交联剂为 EDC和NHS溶于去离子水中配制成的0.5M交联剂溶液, EDC与NHS在水中的摩尔比为1:0.5,EDC/NHS交联剂用量为(100~300)μL/ (0.1~0.3mg纳米铜),优选250μL/0.15mg纳米铜。
进一步地,所述的透明质酸用量为(0.003~0.005)g/ (0.1~0.3mg纳米铜),优选为0.004g/0.15mg纳米铜。
进一步地,所述的鼠李糖脂用量为每mL原料总体积加入鼠李糖脂7~15mg。
进一步地,所述的负载药物,每0.1~0.3mg纳米铜负载0.004~0.008g药物,优选为每0.15mg纳米铜负载0.005g药物,负载药物优选为抗肿瘤药物顺铂(CDDP)或紫杉醇。
一种上述铜纳米粒凝胶载药系统的制备方法,步骤包括:
1)按配比取各原料,将纳米铜加入到灭过菌的去离子水中,超声20min,混合均匀,配制为300μg/mL纳米铜溶液;
2)将聚γ-谷氨酸,加入到灭过菌的去离子水中,搅拌溶解,配制为0.05~0.3g/mL的透明溶液,然后向透明溶液中加入步骤1)配制的纳米铜溶液,搅拌均匀,得到纳米铜的聚γ-谷氨酸溶液;
步骤2)中,纳米铜的聚γ-谷氨酸溶液中聚γ-谷氨酸和纳米铜的质量浓度比为50~90:0.1~0.3;
3)将透明质酸加入到步骤2)的纳米铜的聚γ-谷氨酸溶液中,搅拌均匀,再加入壳寡糖,搅拌均匀,形成均一溶液;
4)将步骤3)均一溶液微波加热9~15s,继续搅拌,直至形成澄清透明溶液;
5)将步骤4)澄清透明溶液冷却至室温,加入负载药物,继续搅拌,形成混合溶液;
6)称鼠李糖脂加入到步骤5)混合溶液中,继续搅拌,形成稳定均一的混合溶液,然后加入交联剂EDC/NHS,搅拌直至形成凝胶;
7)将步骤6)制备好的凝胶, 37℃恒温温育24h,即得铜纳米粒凝胶载药系统。
上述铜纳米粒凝胶载药系统的应用,可用于制备医药产品、护肤产品以及药物负载;尤其适用于创伤、烧伤等伤口中做伤口敷料,促进伤口的快速愈合,抑制伤口处细菌的繁殖;或者做成面膜、护手霜等。
铜离子和银离子、金离子一样,具有较高的抑菌效果,但是因其属于重金属离子,当浓度过大时,就会对细胞产生毒害作用,从而限制了铜离子在医药方面的应用,并且在离子的状态下,铜很容易和其它的物质发生化学反应,效果不好;而本发明发现在纳米状态下,通过限定其含量,可消除对细胞的毒害作用,并且由于其小尺寸效应,强大的比表面积,在杀菌方面,效果显著。
将铜纳米和聚γ-谷氨酸凝胶特异性结合,建立了一种新型铜纳米粒凝胶载药系统,开启了铜纳米在抑菌方面和药物方面的新应用。将其作为一种新型的载药系统,可以特异性的结合一些治疗疾病、抑菌药物、美容养颜药等,做出具有多种功能的敷料产品,在医疗技术,护肤美容等方面,具有重要的应用价值。
本发明铜纳米粒凝胶载药系统,纳米铜使得体系具有较好的抑菌效果,透明质酸作为稳定剂,制备得到的凝胶体系,溶胀性能良好,具有较高的保水性,失水率很低,鼠李糖脂作为生物活性分散剂,使得该凝胶体系药物包裹率较高,载药量较高,并且具有较高的可降解性,溶胀性能较好,原料廉价易得,生产工艺简单。该铜纳米粒凝胶载药系统,可用于医疗产品,尤其适用于创伤、烧伤等伤口中做伤口敷料,以及扭伤处用于活血化瘀,消除肿胀的膏药等,也可应用到护肤产品当中,如面膜、护手霜等。
附图说明
图1为不同含量的铜纳米对载药量的影响;
图2为MTT实验中不同铜纳米添加量对小鼠细胞存活率的影响。
具体实施方式
下面结合具体实施方案,来进一步阐述本发明。并认为,这些实施例仅用于说明本发明,而不用于限制本发明的范围。
实施例1
一种新型铜纳米粒凝胶载药系统的制备,步骤为:
1)按配比取各原料,将纳米铜(50nm)加入到30mL灭过菌的去离子水中,超声20min,混合均匀,配制为300μg/mL铜纳米溶液;
2)取0.7g聚γ-谷氨酸,加入到5mL灭过菌的去离子水中,搅拌溶解,配制为0.14g/mL的透明溶液,然后向透明溶液中加入5mL步骤1)配制的纳米铜溶液,搅拌均匀,得到纳米铜的聚γ-谷氨酸溶液(聚γ-谷氨酸和纳米铜的质量浓度比为70:0.15);
3)称取0.04g透明质酸加入到步骤2)的纳米铜的聚γ-谷氨酸溶液当中,搅拌均匀,再加入0.05g壳寡糖,搅拌均匀,形成均一溶液;
4)将步骤3)均一溶液微波加热10s,连续搅拌,直至形成澄清透明溶液;
5)将步骤4)澄清透明溶液冷却至室温,以抗癌药物顺铂(CDDP)作为试验药物,称取药物顺铂(CDDP)0.005g,加入上述冷却至室温的步骤4)溶液中,继续搅拌,形成混合溶液;
6)称取0.013g鼠李糖脂加入到步骤5)混合溶液中,继续搅拌,形成稳定均一的混合溶液,然后加入交联剂0.0192gEDC,0.006gNHS,搅拌5min直至形成凝胶。
7)将步骤6)制备好的凝胶, 37℃恒温温育24h后,即得铜纳米粒凝胶载药系统。
实施例1所得到的铜纳米粒凝胶载药系统,具有致密的三维网状结构,凝胶交联度35.4%以上,铜纳米包含率为94.24%,药物包裹率达到52.67%,载药量达到3.75%,吸水度为36.7g/g,凝胶交联度达到34.27%以上,与其他产品相比较,明显的加大了药物的包裹率以及载药量,对大肠杆菌,金黄色葡萄球菌的抑菌效率都非常好,其中,对大肠杆菌的抑菌效率达到86.73%,对金黄色葡萄球菌的抑菌效率到达82.91%,经MTT细胞毒性实验证明,与阴性对照材料相比,荷兰鼠小鼠细胞存活率到达58%,说明细胞毒性较低,凝胶保水性较高,生物相容性较好,符合医疗产品的相关规定。
实施例2
一种新型铜纳米粒凝胶载药系统的制备,步骤为:
1)按配比取各原料,将纳米铜加入到灭过菌的去离子水中,超声20min,混合均匀,配制为300μg/mL铜纳米溶液;
2)取0.7g聚γ-谷氨酸,加入到7.5mL灭过菌的去离子水中,搅拌溶解,配制为0.09g/mL的透明溶液,然后向透明溶液中加入步骤1)配制的纳米铜溶液,搅拌均匀,得到纳米铜的聚γ-谷氨酸溶液(聚γ-谷氨酸和纳米铜的质量浓度比为93.3:0.1);
3)称取0.04g透明质酸加入到步骤2)的纳米铜的聚γ-谷氨酸溶液当中,搅拌均匀,再加入壳寡糖,搅拌均匀,形成均一溶液;
4)将步骤3)均一溶液微波加热15s,继续搅拌,直至形成澄清透明溶液;
5)将步骤4)澄清透明溶液冷却至室温,以抗肿瘤药物紫杉醇作为试验药物,称取药物紫杉醇0.008g,加入上述冷却至室温的步骤4)溶液中,继续搅拌,形成混合溶液;
6)称取0.013g鼠李糖脂加入到步骤5)混合溶液中,继续搅拌,形成稳定均一的混合溶液;然后加入交联剂0.0192gEDC,0.006gNHS,搅拌5min直至形成凝胶;
7)将步骤6)制备好的凝胶, 37℃恒温温育24h后,即得铜纳米粒凝胶载药系统。
实施例2所得到的铜纳米粒凝胶载药系统,具有致密的三维网状结构,铜纳米包含率为94.86%,药物包裹率达到75 %,载药量达到8.75%,吸水度为39.74g/g,凝胶交联度达到38.53%,与其他产品相比较,明显的加大了药物的包裹率以及载药量,对大肠杆菌,金黄色葡萄球菌的抑菌效率都非常好,其中,对大肠杆菌的抑菌效率达到82.53%,对金黄色葡萄球菌的抑菌效率到达75.82%,经MTT细胞毒性实验证明,与阴性对照材料相比,荷兰鼠小鼠细胞存活率到达67%,说明细胞毒性较低,生物相容性较好,凝胶保水性较高,符合医疗产品的相关规定。
实施例3
一种新型铜纳米粒凝胶载药系统的制备,步骤为:
1)按配比取各原料,将纳米铜加入到灭过菌的去离子水中,超声20min,混合均匀,配制为300μg/mL纳米铜溶液;
2)取0.7g聚γ-谷氨酸,加入到2.5mL灭过菌的去离子水中,搅拌溶解,配制为0.28g/mL的透明溶液,然后向透明溶液中加入7.5mL步骤1)配制的纳米铜溶液,搅拌均匀,得到纳米铜的聚γ-谷氨酸溶液(聚γ-谷氨酸和纳米铜的质量浓度比为124.4:0.1);
3)称取0.04g透明质酸加入到步骤2)的纳米铜的聚γ-谷氨酸溶液当中,搅拌均匀,再加入壳寡糖,搅拌均匀,形成混合均一溶液;
4)将步骤3)均一溶液微波加热15s,继续搅拌,直至形成澄清透明溶液;
5)步骤4)澄清透明溶液冷却至室温,以抗癌药物顺铂(CDDP)作为试验药物,称取药物0.005g,加入上述冷却至室温的步骤4)溶液中,继续搅拌,形成混合溶液;
6)称取0.013g鼠李糖脂加入到上述步骤5)混合溶液中,继续搅拌,形成稳定均一的混合溶液,然后
加入交联剂0.0192gEDC,0.006gNHS,搅拌5min直至形成凝胶;
7)将步骤6)制备好的凝胶, 37℃恒温温育24h后,即得铜纳米粒凝胶载药系统。
实施例3所得到的铜纳米粒凝胶载药系统,具有致密的三维网状结构,铜纳米包含率为98.35%,药物包裹率达到60%,载药量达到5.75%,吸水度达到40.23g/g,凝胶交联度39.65%以上,与其他产品相比较,明显的加大了药物的包裹率以及载药量,对大肠杆菌,金黄色葡萄球菌的抑菌效率都非常好,其中,对大肠杆菌的抑菌效率达到93.68%,对金黄色葡萄球菌的抑菌效率到达95.79%,经MTT细胞毒性实验证明,与阴性对照材料相比,荷兰鼠小鼠细胞存活率到达52%,说明细胞毒性较低,凝胶保水性较高,生物相容性较好,符合医疗产品的相关规定。
实施例4
添加不同比例铜纳米对载药量以及MTT细胞毒性的影响
添加不同的铜纳米,浓度从300、225、150、100、75、50μg/mL的加量,以不添加纳米铜为阴性对照,如图1所示,铜纳米添加量为150μg/mL时,与未添加铜纳米制备的凝胶载药系统相比,顺铂药物的载药量达到25.62%,如图2所示,铜纳米添加量为150μg/mL时,经MTT细胞毒性试验验证,此浓度下荷兰鼠小鼠细胞存活率到达67%,说明细胞毒性较低,生物相容性较好。
对比例1
与实施例1不同之处在于3)不添加透明质酸。
对比例1的步骤 6)搅拌形成凝胶时间需至少12h;而实施例1加入透明质酸的,5min内形成凝胶。对比例1得到的铜纳米粒凝胶载药系统,经扫描电镜扫描发现,凝胶形成三维网状结构孔径大小在10μm以上,而实施例1的孔径大小在5~10μm之间;吸水度仅为实施例1的2/3,纳米铜的包含率,也仅为其3/4左右,载药量相对实施例1的3.75%,仅为1.58%,抑菌率较低,对大肠杆菌的为53.28%,对金黄色葡萄球菌的为48.85%。相比较实施例1,实施例1得到的铜纳米粒凝胶载药系统,在保水性、抑菌性、药物负载率和包裹率方面具有更好的效果,也具有更优的使用效果。
对比例2
与实施例1不同之处在于3)不添加鼠李糖脂。
对比例2得到的铜纳米粒凝胶载药系统,经扫描电镜扫描发现,凝胶形成三维网状结构孔径大小在10μm左右;吸水度仅为实施例1的3/4,铜纳米的包含率较低,也仅为其2/5左右,载药量相对实施例1的3.75%,仅为1.28%,抑菌率相对较低,对大肠杆菌的为47.32%,对金黄色葡萄球菌的为42.56%。相比较对比例1,实施例1中添加生物活性表面剂,也作为药物分散剂,使得凝胶载药系统的载药量显著得到提高,加大了药物的载药量,以及纳米铜的包裹率,使得凝胶具有更优的使用效果。
对比例3
一种纳米粒凝胶载药系统的制备,将实施例1中原料纳米铜替换为纳米银,步骤同实施例1。
对比例3所得到的银纳米粒凝胶载药系统,结构为较大的孔状、网状结构,经扫描电镜发现,孔径大小在30~45μm之间,吸水度仅为实施例1的1/3,纳米银的包含率为23.8%,载药量仅为1.06%,对大肠杆菌的抑菌效率82.5%,对金黄色葡萄球菌的抑菌效率78.6%,经MTT细胞毒性实验证明,与阴性对照材料的比值接近0.8,与对比例1相比,抑菌效果相差不大,但是实施例1的铜纳米颗粒的包含率以及药物的载药量效果要远远大于对比例1,具有更好的应用价值。
Claims (7)
1.一种铜纳米粒凝胶载药系统,其特征在于:为致密的三维网状多孔结构,凝胶交联度35.4%以上,纳米铜包含率为98.84~99.86%,药物负载率为95.67~97.48%,吸水度为35.5~39.7g/g,药物包裹率为47.82~59.94%;所述铜纳米粒凝胶载药系统,制备原料包括:纳米铜、壳寡糖、聚γ-谷氨酸、EDC/NHS交联剂、透明质酸、鼠李糖脂和负载药物;
所述的纳米铜与壳寡糖、聚γ-谷氨酸的质量比为0.1~0.3: 2~5:50~90;
所述的 EDC/NHS交联剂为 EDC和NHS溶于去离子水中配制成的0.5M交联剂溶液, EDC与NHS在水中的摩尔比为1:0.5,EDC/NHS交联剂用量为100~300μL/ 0.1~0.3mg纳米铜;
所述的鼠李糖脂用量为每mL原料总体积加入鼠李糖脂7~15mg;
所述的透明质酸用量为0.003~0.005g/0.1~0.3mg纳米铜;
所述的负载药物,每0.1~0.3mg纳米铜负载0.004~0.008g药物;
所述的铜纳米粒凝胶载药系统的制备方法包括以下步骤:
1)按配比取各原料,将纳米铜加入到灭过菌的去离子水中,超声20min,混合均匀,配制为300μg/mL纳米铜溶液;
2)将聚γ-谷氨酸,加入到灭过菌的去离子水中,搅拌溶解,配制为0.05~0.3g/mL的透明溶液,然后向透明溶液中加入步骤1)配制的纳米铜溶液,搅拌均匀,得到纳米铜的聚γ-谷氨酸溶液;
步骤2)中,纳米铜的聚γ-谷氨酸溶液中聚γ-谷氨酸和纳米铜的质量浓度比为50~90:0.1~0.3;
3)将透明质酸加入到步骤2)的纳米铜的聚γ-谷氨酸溶液中,搅拌均匀,再加入壳寡糖,搅拌均匀,形成均一溶液;
4)将步骤3)均一溶液微波加热9~15s,继续搅拌,直至形成澄清透明溶液;
5)将步骤4)澄清透明溶液冷却至室温,加入负载药物,继续搅拌,形成混合溶液;
6)称鼠李糖脂加入到步骤5)混合溶液中,继续搅拌,形成稳定均一的混合溶液,然后加入交联剂EDC/NHS,搅拌直至形成凝胶;
7)将步骤6)制备好的凝胶, 37℃恒温温育24h,即得铜纳米粒凝胶载药系统。
2.根据权利要求1所述的铜纳米粒凝胶载药系统,其特征在于:所述的纳米铜,粒度为50nm。
3.根据权利要求1所述的铜纳米粒凝胶载药系统,其特征在于: 所述EDC/NHS交联剂用量为250μL/0.15mg纳米铜。
4.根据权利要求1所述的铜纳米粒凝胶载药系统,其特征在于:所述的透明质酸用量为0.004g/0.15mg纳米铜。
5.根据权利要求1所述的铜纳米粒凝胶载药系统,其特征在于:所述的负载药物为每0.15mg纳米铜负载0.005g药物。
6.根据权利要求1所述的铜纳米粒凝胶载药系统,其特征在于:所述的负载药物为顺铂或紫杉醇。
7.一种权利要求1~6任一项所述铜纳米粒凝胶载药系统的应用,其特征在于:所述的铜纳米粒凝胶载药系统用于药物负载,用于创伤、烧伤伤口中做伤口敷料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710591620.0A CN107362130B (zh) | 2017-07-19 | 2017-07-19 | 一种铜纳米粒凝胶载药系统及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710591620.0A CN107362130B (zh) | 2017-07-19 | 2017-07-19 | 一种铜纳米粒凝胶载药系统及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107362130A CN107362130A (zh) | 2017-11-21 |
CN107362130B true CN107362130B (zh) | 2021-03-02 |
Family
ID=60307380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710591620.0A Active CN107362130B (zh) | 2017-07-19 | 2017-07-19 | 一种铜纳米粒凝胶载药系统及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107362130B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107753347B (zh) * | 2017-11-28 | 2020-12-01 | 曲阜师范大学 | 一种水凝胶酸石榴粉末护肤品及其制备方法、应用 |
CN108552169B (zh) * | 2018-05-09 | 2020-10-30 | 曲阜师范大学 | 一种缓释高效聚γ-谷氨酸/十二烷基二甲基苄基氯化铵纳米杀菌剂及其制备方法、应用 |
CN112402688B (zh) * | 2020-12-18 | 2022-08-30 | 曲阜师范大学 | 一种生物相容性且抗菌的快速止血纳米材料及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102171234A (zh) * | 2008-08-05 | 2011-08-31 | 康奈尔大学 | 光交联核酸水凝胶 |
CN102266582A (zh) * | 2011-06-17 | 2011-12-07 | 北京化工大学常州先进材料研究院 | 载有药物纳米纤维医用敷料制备方法 |
CN102321256A (zh) * | 2011-09-06 | 2012-01-18 | 南开大学 | 生物相容性γ-聚谷氨酸水凝胶制备方法 |
CN103977447A (zh) * | 2014-05-30 | 2014-08-13 | 天津爱若莉生物科技有限公司 | 负载SOD的γ-聚谷氨酸水凝胶制备方法 |
CN105295365A (zh) * | 2015-11-27 | 2016-02-03 | 新疆康润洁环保科技股份有限公司 | 一种制备γ-聚谷氨酸吸水材料的方法 |
CN106832439A (zh) * | 2017-03-26 | 2017-06-13 | 广州市芯检康生物科技有限公司 | 一种用于全血成分保护的新型气凝胶多功能即用型复合材料及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7364879B2 (en) * | 2003-12-19 | 2008-04-29 | Tung Hai Biotechnology Corporation | Stable biodegradable, high water absorbable polyglutamic acid hydrogel by 3-dimensional cross-linking and its preparation method |
-
2017
- 2017-07-19 CN CN201710591620.0A patent/CN107362130B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102171234A (zh) * | 2008-08-05 | 2011-08-31 | 康奈尔大学 | 光交联核酸水凝胶 |
CN102266582A (zh) * | 2011-06-17 | 2011-12-07 | 北京化工大学常州先进材料研究院 | 载有药物纳米纤维医用敷料制备方法 |
CN102321256A (zh) * | 2011-09-06 | 2012-01-18 | 南开大学 | 生物相容性γ-聚谷氨酸水凝胶制备方法 |
CN103977447A (zh) * | 2014-05-30 | 2014-08-13 | 天津爱若莉生物科技有限公司 | 负载SOD的γ-聚谷氨酸水凝胶制备方法 |
CN105295365A (zh) * | 2015-11-27 | 2016-02-03 | 新疆康润洁环保科技股份有限公司 | 一种制备γ-聚谷氨酸吸水材料的方法 |
CN106832439A (zh) * | 2017-03-26 | 2017-06-13 | 广州市芯检康生物科技有限公司 | 一种用于全血成分保护的新型气凝胶多功能即用型复合材料及其制备方法 |
Non-Patent Citations (2)
Title |
---|
Rhamnolipid biosurfactant: Recovery, characterization and evaluation of its effect on antibiotic delivery from a physical hydrogel;P. Sheikhpour et al;《Research in Pharmaceutical Sciences》;20121231;第7卷(第5期);说明书第[0002]段,第[0009]-[0011]段 * |
γ-聚谷氨酸/壳聚糖/纳米银复合水凝胶的制备和表征;王建涛等;《离子交换与吸附》;20160831;第32卷(第4期);第297页第2-3段;第298页第1-2段,第4-5段;第300页第2-3段;第301页第1-2段;第304页第1段 * |
Also Published As
Publication number | Publication date |
---|---|
CN107362130A (zh) | 2017-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kanikireddy et al. | Carboxymethyl cellulose-based materials for infection control and wound healing: A review | |
Iacob et al. | An overview of biopolymeric electrospun nanofibers based on polysaccharides for wound healing management | |
Zhang et al. | Preparation of alginate-based biomaterials and their applications in biomedicine | |
Lu et al. | In situ reduction of silver nanoparticles by chitosan-l-glutamic acid/hyaluronic acid: Enhancing antimicrobial and wound-healing activity | |
Chen et al. | Metal-organic frameworks for improving wound healing | |
Sadeghianmaryan et al. | Curcumin‐loaded electrospun polycaprolactone/montmorillonite nanocomposite: wound dressing application with anti‐bacterial and low cell toxicity properties | |
Colino et al. | Recent advances in functionalized nanomaterials for the diagnosis and treatment of bacterial infections | |
Alven et al. | Fabrication of hybrid nanofibers from biopolymers and poly (Vinyl alcohol)/poly (ε-caprolactone) for wound dressing applications | |
Qian et al. | Copper-hydrazide coordinated multifunctional hyaluronan hydrogels for infected wound healing | |
Wsoo et al. | Vitamin D3-loaded electrospun cellulose acetate/polycaprolactone nanofibers: Characterization, in-vitro drug release and cytotoxicity studies | |
Darvishi et al. | Ultrasound-assisted synthesis of MIL-88 (Fe) coordinated to carboxymethyl cellulose fibers: A safe carrier for highly sustained release of tetracycline | |
Wen et al. | Preparation and characterization of protein-loaded electrospun fiber mat and its release kinetics | |
CN107362130B (zh) | 一种铜纳米粒凝胶载药系统及其制备方法和应用 | |
CN107233301B (zh) | 一种纳米颗粒凝胶载药系统的快速制备方法 | |
Tavakol et al. | Investigating the effects of particle size and chemical structure on cytotoxicity and bacteriostatic potential of nano hydroxyapatite/chitosan/silica and nano hydroxyapatite/chitosan/silver; as antibacterial bone substitutes | |
Türk et al. | A novel multifunctional NCQDs-based injectable self-crosslinking and in situ forming hydrogel as an innovative stimuli responsive smart drug delivery system for cancer therapy | |
Cai et al. | Curcumin-stabilized silver nanoparticles encapsulated in biocompatible electrospun nanofibrous scaffold for sustained eradication of drug-resistant bacteria | |
Mao et al. | Preparation and evaluation of a novel alginate-arginine-zinc ion hydrogel film for skin wound healing | |
Shariati et al. | Graphene-based materials for inhibition of wound infection and accelerating wound healing | |
Wang et al. | Copper boron–imidazolate framework incorporated chitosan membranes for bacterial-infected wound healing dressing | |
Jiang et al. | Rational design of porous structure-based sodium alginate/chitosan sponges loaded with green synthesized hybrid antibacterial agents for infected wound healing | |
Sabarees et al. | Recent advances in silver nanoparticles containing nanofibers for chronic wound management | |
Xu et al. | Mild heat-assisted polydopamine/alginate hydrogel containing low-dose nanoselenium for facilitating infected wound healing | |
Jadoun et al. | Silver nanoparticles with natural polymers | |
Ullah et al. | Mussel bioinspired, silver-coated and insulin-loaded mesoporous polydopamine nanoparticles reinforced hyaluronate-based fibrous hydrogel for potential diabetic wound healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |